<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62228">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104336</url>
  </required_header>
  <id_info>
    <org_study_id>EPI743-13-024</org_study_id>
    <nct_id>NCT02104336</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of EPI-743 in Children With Pearson Syndrome</brief_title>
  <official_title>An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Axio Research. LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Edison Pharmaceuticals Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If effective, treatment with EPI-473 should result in a significant reduction in occurrence
      of sepsis, metabolic crisis, hepatic failure and transfusion dependence.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Occurence of episodes of sepsis, metabolic crisis or hepatic faillure</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion avoidance</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic function</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuromuscular function</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Neuromuscular function as assessed by Gross Motor Function Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease severity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease severity as assessed by Newcastle Pediatric Mitochondrial Disease Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic function</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight gain</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic function</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pancreatic function as assessed by insulin requirement and hemoglobin A1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortalilty</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Dose Limiting SAEs</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any adverse event greater than or equal to grade 3 that is deemed related to treatment with EPI-743 and not related to underlying disease</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pearson Syndrome</condition>
  <arm_group>
    <arm_group_label>EPI-743</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg EPI-743 to be administered three times per day for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743</intervention_name>
    <description>EPI-743 is the quinone oxidation product of alpha-tocotrienol</description>
    <arm_group_label>EPI-743</arm_group_label>
    <other_name>Vincerinone (TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically confirmed diagnosis of Pearson syndrome

          -  Age less than 18

          -  Availability of medical history for 12 months prior to enrollment

          -  Abstention from use of CoQ10, vitamin E, lipoic acid and Idebenone 14 days   prior to
             treatment with EPI-743

        Exclusion Criteria:

          -  Allergy to EPI-743, sesame oil or vitamin E

          -  Clinical history of bleeding/ abnormal PT/PTT

          -  Concurrent inborn errors of metabolism

          -  Use of anticoagulant medications

          -  Participation in any interventional study within 30 days of treatment

          -  Use of erythropoietin 30 days prior to trial enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Klein, MD, FACS</last_name>
    <role>Study Chair</role>
    <affiliation>Edison Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Abdenur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrenâ€™s Hospital of Orange County</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Matthew Klein, MD, FACS</last_name>
    <phone>650-641-9211</phone>
    <email>mklein@edisonpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin P. Johnson, BA</last_name>
    <phone>650-641-9212</phone>
    <email>ejohnson@edisonpharma.com</email>
  </overall_contact_backup>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pearson</keyword>
  <keyword>EPI743</keyword>
  <keyword>EPI-743</keyword>
  <keyword>Vincerinone</keyword>
  <keyword>Mitochondrial disorder</keyword>
  <keyword>Mitochondrial disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
